e6a2 BCR-ABL阳性急性髓系白血病对伊马替尼继而达沙替尼的完全分子反应
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
作者信息
Ritchie David S, McBean Michelle, Westerman David A, Kovalenko Sergey, Seymour John F, Dobrovic Alexander
机构信息
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, No. 1 A'Beckett Street, Melbourne, Victoria 8006, Australia.
出版信息
Blood. 2008 Mar 1;111(5):2896-8. doi: 10.1182/blood-2007-08-107508. Epub 2007 Dec 11.
De novo presentation of acute myeloid leukemia (AML) expressing the Philadelphia (Ph) chromosomal abnormality is rare and is associated with a dismal prognosis. To date, reported cases of Ph(+) AML have expressed either the e13a2 or e14a2 BCR-ABL fusion transcripts. We report a unique case of de novo AML expressing the e6a2 fusion transcript and describe disease sensitivity to both imatinib before allogeneic stem-cell transplantation and dasatinib for AML relapse after allogeneic stem-cell transplantation. Furthermore, we report that sustained molecular remission has been achieved despite withdrawal of tyrosine kinase inhibitor (TKI) therapy.
新发表达费城（Ph）染色体异常的急性髓系白血病（AML）较为罕见，且预后不良。迄今为止，报道的Ph（+）AML病例均表达e13a2或e14a2 BCR-ABL融合转录本。我们报告了一例新发表达e6a2融合转录本的AML独特病例，并描述了该疾病在异基因干细胞移植前对伊马替尼以及异基因干细胞移植后AML复发对达沙替尼的敏感性。此外，我们报告尽管停用了酪氨酸激酶抑制剂（TKI）治疗，但仍实现了持续分子缓解。
Zotero 插件